KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Edwards Lifesciences (EW) Receivables - Other (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Receivables - Other data on record, last reported at $252.5 million in Q4 2025.

  • For Q4 2025, Receivables - Other rose 113.44% year-over-year to $252.5 million; the TTM value through Dec 2025 reached $252.5 million, up 113.44%, while the annual FY2025 figure was $252.5 million, 113.44% up from the prior year.
  • Receivables - Other reached $252.5 million in Q4 2025 per EW's latest filing, up from $199.5 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $252.5 million in Q4 2025 and bottomed at $42.8 million in Q2 2022.
  • Average Receivables - Other over 5 years is $89.4 million, with a median of $62.4 million recorded in 2023.
  • Peak YoY movement for Receivables - Other: tumbled 47.87% in 2021, then surged 266.49% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $82.7 million in 2021, then plummeted by 32.16% to $56.1 million in 2022, then rose by 0.89% to $56.6 million in 2023, then skyrocketed by 109.01% to $118.3 million in 2024, then soared by 113.44% to $252.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $252.5 million in Q4 2025, $199.5 million in Q3 2025, and $205.6 million in Q2 2025.